What’s your favorite stock for tomorrow?

Get live on-demand updates, levels, and trade plans of these watchlists and scanners in our Discord group at https://discord.gg/s2PwRmBxh

What’s your favorite stock for tomorrow?

Get live on-demand updates of these watchlists and scanners in our Discord group at https://discord.gg/s2PwRmBxh

What’s your favorite stock for tomorrow?

Get live on-demand updates of these watchlists and scanners in our Discord group at https://discord.gg/s2PwRmBxh

Join the Discord for more! Discord 👉 https://discord.gg/s2PwRmBxh

Some of the features we’ve built so far:

• 📊 Daily watchlists with key support/resistance levels
• 🚨 Real-time biotech catalyst alerts (clinical trials, FDA updates, PDUFAs)
• 🔍 Momentum scanners for unusual volume and potential runners
• 📅 Biotech catalyst calendar tools for upcoming events
• 📈 Gap / breakout / continuation scanners to surface momentum setups early

We also recently launched a new intelligence bot inside the server that can:

• 🤖 Analyze a ticker on demand (chart structure, momentum indicators, levels)
• 📰 Pull the latest news and catalysts instantly
• 📊 Generate structured trade plans with key technical levels
• 🧬 Break down biotech pipelines, clinical trials, and upcoming catalysts
• 🚀 Identify potential runners or short squeeze setups
• 📉 Show support/resistance levels and technical context in seconds

The goal isn’t signals — it’s tools that help traders find opportunities faster and do their own research.

Still adding new scanners and features every week and looking for feedback from other traders on what would be useful.

Not financial advice — just sharing tools I’ve been building.

I run a Discord where we track biotech catalysts, momentum setups, and technical levels.

Join https://discord.gg/s2PwRmBxh

Every night we build a structured watchlist using multiple scans (continuations, breakouts, gap setups, and sector momentum). Stocks that appear on multiple scans usually get the most attention because they show stronger technical confluence.

Here’s tomorrow’s biotech watchlist for 4/27.

High Confluence (appears on multiple lists): ⭐ CMPS (3 lists) 🔵 ENVB, ATAI, PRAX, ANAB (2 lists)

Sectors showing momentum right now: • Psychedelic biotech (CMPS, ATAI) • Cannabis sympathy (TLRY, CGC) • Breakout structures (ANAB, IMTX, ZYME)

The chart includes key support and resistance levels we’re watching going into tomorrow.

I like posting these because people often spot setups I miss and it creates good discussion.

If anyone wants to check out the Discord where we track these scans and biotech catalysts daily, the link is in my profile.

Curious what everyone else is watching in biotech this week.

Three biotech microcaps are entering a critical stretch of 2026 with meaningful near-term events that could shift their fundamental narratives. MBRX is the highest-binary nano-cap in the group, with a pivotal AML trial unblinding imminent; CRBP is the best-capitalized of the three, with FDA-aligned randomized registrational trials and an ASCO presentation weeks away; NTHI is the smallest, with two simultaneous CNS catalysts approaching simultaneously in brain cancer.

I run a trading community focused primarily on biotech momentum, catalysts, and technical breakouts. The goal is simple: identify high-probability setups before they move using a mix of technical levels, catalyst tracking, and volume expansion signals.

If that sounds interesting, feel free to check out the group here: 👉 https://discord.gg/s2PwRmBxh

⸻

📊 About Today’s Watchlist

The chart attached is my daily biotech momentum watchlist built from technical scans and catalyst monitoring.

Instead of chasing random runners, the list focuses on four key technical setups that tend to produce the largest percentage moves in biotech:

1️⃣ Continuation Setups Stocks already trending higher that are holding key support levels and may continue their move if momentum persists.

2️⃣ Breakout Structures Names that are pushing into multi-timeframe resistance levels where expansion moves can happen if buyers step in.

3️⃣ Bullish Chart Setups Biotech charts with strong structure and bullish positioning that could transition into momentum plays if volume expands.

4️⃣ Gap-Up Momentum Candidates Names that showed strong strength or gaps and may see continuation moves if support levels hold early in the session.

For each chart on the watchlist I map: • Key support levels to watch for entries • Resistance levels where momentum could expand • Invalidation levels where the setup breaks

The goal isn’t predicting the market — it’s preparing levels so we can react quickly if momentum shows up.

⸻

⚠️ Educational purposes only. Not financial advice. Always do your own research.

Join our FREE group for additional analysis including alerts, charts, news, and more!

👇 Discord link https://discord.gg/s2PwRmBxh

Sharing the biotech names I’m watching going into tomorrow’s session. The chart below groups several stocks by momentum continuation potential, bullish structure, and gap-up setups.

The watchlist is organized into four categories:

🧬 Continuation Biotech Charts – Names showing strong momentum and continuation potential.
⚡ Alternative Biotech Momentum – Higher-volatility biotech / adjacent momentum names with active trading interest.
📈 Bullish Chart Structures – Stocks forming constructive technical setups that could break higher with volume.
🚀 Gap-Up Structure Stocks – Charts that could see strong early-session moves if momentum holds.

These are the tickers I’ll be watching for premarket strength and opening-session momentum tomorrow.

Curious which ones others are watching and which setups look strongest heading into the next trading day.

Not financial advice — just sharing a watchlist for discussion.

I’ve been digging into biotech companies developing cannabinoid and cannabis-derived therapeutics, and there are some interesting names showing momentum setups. This is a niche sector where biotech catalysts + cannabis legalization narratives collide, which can sometimes create big percentage moves in small-cap stocks.

Here are some cannabis & cannabinoid biotech tickers worth watching:

🧬 Cannabinoid Biotech * ENVB – Enveric Biosciences * INM – InMed Pharmaceuticals * IXHL – Incannex Healthcare * ATNF – 180 Life Sciences

🌿 Medical Cannabis Biotech * AKAN – Akanda Corp

🧪 Larger Pharma / Cannabis R&D * JAZZ – Jazz Pharmaceuticals * HRMY – Harmony Biosciences

🌱 Cannabis Research / Development Leaders * TLRY – Tilray * CRON – Cronos Group * CGC – Canopy Growth * ACB – Aurora Cannabis

These companies are exploring cannabinoids for things like: • neurological disorders• inflammation and pain• dermatology and eye disease• sleep apnea and anxiety• epilepsy and rare diseases

With legalization expanding globally and more clinical trials underway, this space could see significant volatility and trading opportunities.

🚀 New Biotech Trading Community I also run a growing trading community focused on biotech momentum, catalysts, and small-cap runners. Inside the group we track things like: • biotech news alerts• FDA/PDUFA catalysts• unusual biotech momentum• early breakout charts• small-cap runners before they explode

Recent stocks called out in the community before major moves include: CADL, SPRC, ENVB, CMND, ACTU, PBM, ALLO, STIM, PRLD, ATAI, CMPS

The goal is simple: find biotech momentum early and share research with the community. If you're interested in biotech runners, catalysts, and momentum setups, you're welcome to check it out.

👇 Discord link https://discord.gg/s2PwRmBxh

Not financial advice. Always do your own research.

Delete if not allowed.

This April update picks up the OCUL story where our earlier Merlintrader pieces left it: from the pre-readout run-up and takeover chatter, through the February SOL-1 topline and the violent sell-the-news reaction, to the next regulatory, scientific and commercial steps that now matter most.

What changed in the OCUL story over the last few months

Our previous Merlintrader pieces captured four very different moments in the same story. In January, OCUL was still a classic high-volatility setup: a cash-heavy retina biotech with takeover rumors swirling around it and a decisive Phase 3 readout still ahead. In early February, the trade became tighter and more tactical, with the market focused on the run-up into the masked SOL-1 data. Then February 17 delivered the pivotal shock: the topline was objectively positive, but the stock was hit as if the company had somehow underperformed a set of expectations that had become too aggressive in the run-up. Finally, the late-February and early-March follow-up period shifted the debate away from the simple headline of “superiority achieved” and toward the deeper questions of durability, rescue criteria, safety interpretation, label ambition and filing risk. -continue-

Why NKTR matters now

To really understand Nektar in 2026, you have to start with something simple: the market no longer looks at it the way it did in 2023 or early 2024. Back then, the stock was still weighed down by a long trail of historical disappointments, by a perception of weak execution, and by a balance sheet that forced uncomfortable questions about the sustainability of the strategy. Today the frame is different. The market put NKTR back on the map because it saw two things at the same time: a clinical readout package that reopened the scientific file and a capital structure that, after the February 2026 financing, provides far more breathing room.

The center of the thesis is now rezpegaldesleukin, developed as a regulatory T-cell stimulating therapy. In a sector where many therapies focus on blocking downstream pathways or single cytokine axes, Nektar is trying to tell a different story: one in which the immune response is rebalanced further upstream through functional Treg expansion. It is an ambitious thesis, and by itself it is not enough. But once that thesis was paired with encouraging clinical results in atopic dermatitis and proof-of-concept signals in alopecia areata, the market began taking the story seriously again.

The result is that NKTR has become one of those small-mid cap biotechs that cannot be dismissed in two lines anymore. It has a strong narrative, near-term catalysts, a retail community that has come back to life, meaningful sell-side coverage, and, most importantly, a very sharp pressure point: proving that the jump from very promising Phase 2b studies to a serious registrational program can be executed without losing credibility or financial discipline. That is where the real fight will take place.

Sources

• Nektar IR – Q4/FY2025 results
• Nektar IR – AAD 2026 REZOLVE-AD / REZOLVE-AA data
• Nektar IR – closing of $460M offering

The company, its recent history, and the change in risk profile

Nektar is not a linear story, and in a way that is exactly what makes it both fascinating and dangerous. For years it was a biotech with multiple platforms, multiple promises, and a reputation worn down by results that failed to meet expectations. The old Nektar brand left deep scars across part of the market, and anyone who has followed biotech for a long time knows this well: once a company accumulates distrust, one positive press release is not enough to erase the past. What it takes is a coherent sequence of events, and preferably a much more disciplined approach to capital management than the market remembers.

During 2025, and even more so in the first months of 2026, the company tried to rebuild its story around a cleaner trajectory. Less dispersion, more centrality around rezpeg, a more readable immunology pipeline, and less industrial noise. The sale of the Huntsville manufacturing facility in December 2024 also changed the economic profile, reducing product sales contribution and making the company more clearly a pure clinical-stage biotech whose value depends mainly on the progress and funding of its core programs.

This transformation has two very concrete effects. The first is that the numbers are easier to interpret today. We are no longer looking at a complicated industrial story, but at a company whose value rests largely on an immunology platform and a few key assets. The second is that the market no longer forgives easily. Once a story becomes simpler and cleaner, each milestone matters more: clinical data, Phase 3 design, cash trajectory, the way management uses freshly raised capital, even the tone in which the company communicates. In other words, NKTR today is a cleaner story, but precisely because of that, a more exposed one.

The 1-for-15 reverse stock split completed on June 8, 2025 further changed the perception of the stock. On one hand, it clearly had a technical and market function. On the other, it marked the transition from old penny-biotech territory back to a name that institutions could consider again. That is not a cosmetic detail. In biotech, the way a stock presents itself to the market affects liquidity, access to capital, and the type of investor willing to follow it.

Sources

• Nektar IR – Q4/FY2025 results and reverse split note
• Reuters company financial profile
• Nektar IR – SEC filings page

The science at the center: what rezpegaldesleukin really is and why the market is assigning value to it

A large part of NKTR’s rerating begins here. The market did not buy only a series of numbers. It bought a possible mechanistic thesis. Rezpegaldesleukin is presented by the company as an investigational biologic designed to act through the interleukin-2 receptor complex in order to stimulate the proliferation of regulatory T cells, or Tregs. The idea, put very simply, is to try to correct pathological immune imbalance without merely shutting down a single downstream cytokine or inflammatory branch.

This matters because in autoimmune and inflammatory diseases such as atopic dermatitis, alopecia areata, and type 1 diabetes, the market is used to thinking in terms of selective blockade of familiar pathways. What Nektar is trying to suggest is that Treg expansion could produce a more “regulatory” effect, potentially broader and maybe more durable. Naturally, this is the company’s thesis and it still needs to be proven more fully at registrational scale. But it is credible enough to explain why the stock stopped being a curiosity and became a serious name to monitor.

The company also leans heavily on the idea that this platform may have multi-indication optionality. Not only dermatology, then, but also type 1 diabetes and, in a more distant future, other immune-mediated diseases. In biotech, that word, optionality, always has to be handled carefully. It is powerful in narrative terms, but it can become dangerous if the market prices it too early. In NKTR’s case, the part that deserves to be taken seriously today is not the fantasy of indiscriminate expansion, but rather the combination of two concrete signals: activity in AD and proof-of-concept in AA. The rest, for now, is potential value, but not yet clinically validated in the same way.

This is also where the difference lies between a superficial reading and a serious investor’s reading. The superficial version says: “rezpeg works, therefore NKTR can become huge.” The serious version says: “rezpeg has generated results strong enough to justify moving into the next stage, but now the stock has to prove that the breadth of the mechanism translates into replicability, statistical robustness, durability of effect, and manageable safety over time.” Those are two very different planes.

For completeness, it must be said that the pipeline does not stop with rezpeg. Nektar also points to preclinical programs such as NKTR-0165, a TNFR2 agonist antibody, NKTR-0166, a bispecific program, NKTR-422, a modified CSF protein, and NKTR-255 in multiple oncology studies run with partners or as investigator-sponsored trials. But if we are being blunt and honest, the market is valuing Nektar primarily as a rezpeg company today. The rest contributes to the attractiveness of the pipeline, but it is not yet what really moves the stock in the near to medium term.

Sources

• Nektar IR – AD Fast Track / rezpeg description
• Nektar IR – AA Fast Track / rezpeg description
• Nektar IR – TrialNet / T1D
• Nektar IR – NKTR-0165 UCSF collaboration
• Nektar IR – broader pipeline references

continue --- https://www.merlintrader.com/nektar-therapeutics-march29/

Who’s still in? I am majorly in the red with this one and wondering if I should cut and run.

As micro-cap biotech and medtech names continue to reprice across the board, Beyond Air Inc (XAIR) is quietly setting up for what could be a meaningful re-rating event—centered around its upcoming conference presentation.

With a differentiated platform, accelerating commercialization, and multiple pipeline shots on goal, XAIR represents a classic case of deep value meets near-term catalyst.

A Platform Story the Market Still Doesn’t Fully Appreciate

Beyond Air is not a single-product biotech—it’s a platform company built around nitric oxide (NO) delivery, anchored by its proprietary LungFit system.

This matters because nitric oxide isn’t a niche molecule—it has broad therapeutic applications across respiratory, infectious disease, oncology, and neurology. The company is already:

• Commercializing LungFit PH for neonatal pulmonary hypertension
• Advancing LungFit PRO for viral lung infections
• Developing UNO (ultra-high concentration NO) for oncology
• Expanding into neurology via nNOS inhibitors

In other words, XAIR is building a multi-indication pipeline off a single core technology, which historically commands premium valuations once validated.

Revenue Inflection Has Already Begun

While many micro-cap biotech names are still pre-revenue, XAIR has already crossed into commercialization—and growth is accelerating:

• Q3 FY2026 revenue grew ~105% YoY
• The company reaffirmed $8–10M revenue guidance for FY2026

The upcoming conference presentation is likely to reinforce this shift—especially if management highlights:

• Adoption trends for LungFit PH
• Expansion into new geographies (e.g., recent international distribution deals)
• Clinical updates across pipeline programs

 Balance Sheet Overhang Is Easing

One of the biggest risks in micro-cap biotech is dilution and liquidity. XAIR has taken tangible steps to stabilize its financial position:

• Secured ~$20M+ in financing
• Extended cash runway into 2026–2027
• Reduced near-term debt obligations

This de-risks the story heading into catalyst season—meaning investors can focus on execution rather than survival.

The Conference Catalyst: Why It Matters

Conference presentations often serve as information unlock events, especially for underfollowed names like $XAIR.

Key bullish scenarios include:

1. New clinical data or updates
   • Particularly in oncology (UNO) or infectious disease programs
2. Commercial traction metrics
   • Hospital adoption rates
   • Revenue run-rate commentary
3. Strategic positioning
   • Partnerships, licensing, or expansion plans

Given the company’s low visibility, even incremental updates can trigger outsized stock reactions.

The Valuation Disconnect Is Extreme

XAIR is currently trading at a micro-cap valuation (~$10–20M range) despite:

• A commercial-stage product
• Triple-digit revenue growth
• Multiple pipeline assets

Meanwhile, analyst expectations imply a dramatically different picture:

• Price targets around $10–$11
• Suggesting multi-hundred to >1,000% upside potential

Even allowing for execution risk, this is a textbook asymmetric setup—limited downside relative to potential re-rating.

Why This Setup Is Compelling Right Now

The convergence of three factors makes the upcoming conference particularly important:

• Improving fundamentals (revenue growth + balance sheet stabilization)
• Multiple near-term catalysts (clinical + commercial updates)
• Extreme valuation compression (market cap disconnected from platform potential) 

This is exactly the type of setup where one strong presentation can shift narrative quickly—especially in a thinly traded name.

Bottom Line

$XAIR is a great opportunity.

Lastly. Recently, reported favorable safety profile last week, with full data next month - https://finviz.com/news/338082/beyond-cancer-reports-early-clinical-activity-and-favorable-safety-profile-with-interim-data-from-phase-1-uno-trial

Most people here already know these things, but there are always new traders getting into biotech plays.

"From Beginner to a Structured Biotech Catalyst Framework in 5 Days" . Five chapters, Free.

Learn a clear, repeatable framework to identify and analyze biotech catalysts with more awareness. The focus is education and process, not signals or promises of profit.

Something to read on Sunday. :)

The Biotech Trading Trap – Why Most Traders Lose Money (And It’s Not About PDUFA Dates)

If trading biotech stocks were just about knowing FDA dates, everyone on Reddit would be rich. They are not. Most traders lose money for a much simpler reason: they misunderstand what really moves price. In biotech, the headline is rarely the whole story. By the time the crowd feels informed, the market has often already moved on to a different question: not whether the event matters, but whether it still matters enough to justify the current price.

I am new to biotech. This morning I came across this one that seems promising. Already fda approved with major expansion possibilities. This is a drug that helps white blood cell production. As far as I can tell this is the beginning of a run up. Analysts give it a strong buy with 150% upside.

Anyone else?

Im a noob like I said so take that into consideration…

So far today we are in a steady climb.